Basilea Capital Markets Day
11 April 2024
Park Hyatt, Zurich
You can find the presentation here.
David Veitch
Chief Executive Officer at Basilea
Adesh Kaul
Chief Financial Officer at Basilea
Marc Engelhardt
M.D., Ph.D.
Chief Medical Officer at Basilea
Oliver A. Cornely
M.D., Ph.D.
Professor of Translational Research, Faculty of Medicine, University of Cologne
Thomas L. Holland
M.D., Ph. D.
Associate Professor of Medicine, Infectious Diseases, Department of Medicine, Duke University
David Veitch
Chief Executive Officer at Basilea
We were delighted to have Professor Oliver A. Cornely and Professor Thomas L. Holland as our guest speakers.
David Veitch, CEO
Adesh Kaul, CFO
incl. Q&A
Marc Engelhardt, M.D., Ph.D., CMO
Invasive fungal infections
Professor Oliver A. Cornely, Professor of Translational Research, Faculty of Medicine, University of Cologne
Staphylococcus aureus bacteremia
Professor Thomas L. Holland, Associate Professor of Medicine, Infectious Diseases, Department of Medicine, Duke University
David Veitch, CEO
Interested in a meeting?
If you have further questions or would like to request a meeting with the Management or IR team, please do not hesitate to reach out to Ms. Dung Tran, Investor Relations Coordinator, at NgocDung.Tran@basilea.com .
Professor of Translational Research, Faculty of Medicine, University of Cologne
Associate Professor of Medicine, Infectious Diseases, Department of Medicine, Duke University
Chief Executive Officer at Basilea
Chief Financial Officer at Basilea
“Basilea is living in exciting times.
We’re on the verge of something big, in the changing world of anti-infectives."
David Veitch | CEO Basilea Pharmaceutica
Basilea Pharmaceutica Ltd, Allschwil
Ms. Dung Tran
P: +41 61 606 12 58
ngocdung.tran@basilea.com